May 8, 2024
(press release)
–
We are pleased to invite investors and analysts to participate in our virtual event on Friday, 31 May 2024, highlighting Roche oncology products and late-stage pipeline assets for solid tumors and malignant hematology including data presented during the congress scientific program from May 31 – June 4, 2024.
16:00 – 17:00 CEST / 15:00 - 16:00 BST
09:00 – 10:00 am CDT / 7:00 – 8:00 am PDT
The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CEST on the day of the event. > click here
Access to virtual event (pre-registration required)
Please pre-register for our webinar here*.
Should you be unable to register for the webinar due to your company IT policy, please send an e-mail to investor.relations@roche.com.
A replay of the webcast will be available via > ir.roche.com
*privacy notice
Best regards,
Bruno Eschli
Head of Investor Relations
Sabine Borngräber
Investor Relations Officer
Roche Investor Relations
Dr. Bruno Eschli
Phone: +41 61 68-75284
e-mail: bruno.eschli@roche.com
Dr. Sabine Borngräber
Phone: +41 61 68-88027
e-mail: sabine.borngraeber@roche.com
Dr. Birgit Masjost
Phone: +41 61 68-84814
e-mail: birgit.masjost@roche.com
Investor Relations North America
Loren Kalm
Phone: +1 650 225 3217
e-mail: kalm.loren@gene.com
* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.
